Emerging Biopharma Market Influence and the Changing CRO Landscape


Recently, TrialSite News commented on a telling IQVIA survey showcasing the rise of “Emerging Biopharma.”  In what used to be solely the territory of “big pharma,” new agile, aggressive and often well-funded private equity-based emerging biopharma operate on the same level.  In 2018, 64% of the 59 new active substances commercialized in 2018 were originated by emerging biopharma. Moreover, just last year 47% of new active substances were launched by emerging biopharma—a fundamental change from a decade ago. The rise of the emerging biopharma could possibly reshape the CRO landscape.
Hence, we read with interest a recent Applied Clinical Trials interview titled “The Changing Needs of Mid-sized Sponsors.”  Editors interviewed Becky Carpenter, Head of North American/Euro Operations at WuXi Clinical, originally launched out of China and now an increasingly well-branded mid-market CRO.  WuXi Clinical is the result of a merger between Research Point Global and WuXi Clinical Development Services.
We encourage the reader to select the link at the bottom to read the entire interview.  In a nutshell, we provide a summary of Ms. Carpenter key market themes.
WuXi Mid-Market CRO Trends Obser...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee